Northwest & Ethical Investments L.P. Grows Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Northwest & Ethical Investments L.P. lifted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 108.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,000 shares of the company’s stock after buying an additional 5,200 shares during the quarter. Northwest & Ethical Investments L.P.’s holdings in Teva Pharmaceutical Industries were worth $180,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Vinva Investment Management Ltd grew its stake in Teva Pharmaceutical Industries by 964.6% in the 3rd quarter. Vinva Investment Management Ltd now owns 217,720 shares of the company’s stock worth $3,801,000 after acquiring an additional 197,270 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 237.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,377,517 shares of the company’s stock worth $60,863,000 after purchasing an additional 2,376,668 shares during the last quarter. Public Sector Pension Investment Board grew its position in shares of Teva Pharmaceutical Industries by 23.4% in the third quarter. Public Sector Pension Investment Board now owns 580,967 shares of the company’s stock valued at $10,469,000 after purchasing an additional 110,300 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Teva Pharmaceutical Industries by 3.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 453,251 shares of the company’s stock valued at $8,168,000 after purchasing an additional 14,372 shares during the last quarter. Finally, BNP Paribas lifted its position in Teva Pharmaceutical Industries by 1,031.1% during the third quarter. BNP Paribas now owns 7,918 shares of the company’s stock worth $143,000 after buying an additional 7,218 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares of the company’s stock, valued at $744,034.48. The trade was a 30.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.55% of the company’s stock.

Analyst Upgrades and Downgrades

TEVA has been the subject of several recent analyst reports. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Barclays upped their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. UBS Group lifted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Teva Pharmaceutical Industries Trading Up 1.3 %

NYSE:TEVA opened at $16.78 on Friday. Teva Pharmaceutical Industries Limited has a 12 month low of $9.35 and a 12 month high of $19.31. The business’s 50-day moving average is $17.56 and its two-hundred day moving average is $17.35. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The firm has a market capitalization of $19.01 billion, a PE ratio of -19.74, a price-to-earnings-growth ratio of 1.29 and a beta of 0.87.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.